InvestorsHub Logo
Followers 25
Posts 3482
Boards Moderated 0
Alias Born 08/21/2014

Re: None

Wednesday, 06/21/2017 7:10:34 AM

Wednesday, June 21, 2017 7:10:34 AM

Post# of 9705
• NIH's National Institute of Allergy and Infectious Diseases (NIAID) exercises its option to advance development of Soligenix's (NASDAQ:SNGX) RiVax, its ricin toxin vaccine, as a countermeasure to prevent the effects of ricin exposure.

• The new funding of ~$2M will support additional animal studies. The total award to date is now $18.7M. If NIAID exercises all of its options, the total award will be $24.7M.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNGX News